Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma

Immunological Reviews

Volumn 188, Issue , 2002, Pages 81-96

  Romero, Pedro ^a,e   Valmori, Danila ^a   Pittet, Mikael J ^a   Zippelius, Alfred ^a   Rimoldi, Donata ^b   Lévy, Frederic ^b   Dutoit, Valérie ^b   Ayyoub, Maha ^f   Rubio Godoy, Verena ^a   Michielin, Olivier ^a,b   Guillaume, Philippe ^b   Batard, Pascal ^a   Luescher, Immanuel F ^b   Lejeune, Ferdy ^a   Liénard, Danielle ^a   Rufer, Nathalie ^c   Dietrich, Pierre Yves ^d   Speiser, Daniel E ^a   Cerottini, Jean Charles ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e Hopital Orthopedique de la Suisse Romande   (Switzerland)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLEUCYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTYROSYLVALINAMIDE; CD4 ANTIGEN; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINAMIDE; MELAN A; MELANOMA ANTIGEN; MELANOMA VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; EPITOPE; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; MELANOMA; METASTASIS; MOLECULAR CLONING; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CHEMISTRY; CYTOTOXICITY; IMMUNOLOGY; INNATE IMMUNITY; MOLECULAR GENETICS; PROTEIN ANALYSIS; REVIEW; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY, ACTIVE; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN INTERACTION MAPPING; RECEPTORS, ANTIGEN, T-CELL; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 18744373312     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18808.x     Document Type: Article

References (81)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
2. Van Pel A, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
3. Wang RF. Human tumor antigens: Implications for cancer vaccine development. J Mol Med 1999;77:640-655.
4. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-716.
5. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
6. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
7. Coulie PG, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
8. Kawakami Y, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
9. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
10. Rivoltini L, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
11. Rimoldi D, et al. Subcellular localization of the melanoma-associated protein Melan-AM-ART-1 influences the processing of its HLA-A2-restricted epitope. J Biol Chem 2001;276:43189-43196.
12. De Mazière AM, et al. The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins. Traffic 2002;3:678-693.
13. Wolfel T, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
14. Topalian SL, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-9465.
15. Kawakami Y, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
16. Tsai V, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997;158:1796-1802.
17. Zhai Y, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 1997;20:15-25.
18. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998;75:451-458.
19. Bettinotti MP, et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: Implications for peptide-based immunotherapy. J Immunol 1998;161:877-889.
20. Morel S, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-117.
21. Romero P, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997;159:2366-2374.
22. Valmori D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-1758.
23. Valmori D, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 1999;11:1971-1980.
24. Skipper JC, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999;82:669-677.
25. Sliz P, et al. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 2001;167:3276-3284.
26. Khan AR, Baker BM, Ghosh P, Biddison WE, Wiley DC. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J Immunol 2000;164:6398-6405.
27. Beck A, et al. Stability and CTL activity of N-terminal glutamic acid containing peptides. J Pept Res 2001;57:528-538.
28. Brinckerhoff LH, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1 (27-35) peptide: Implications for peptide vaccines. Int J Cancer 1999;83:326-334.
29. Blanchet JS, et al. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: Implication for molecular anti-melanoma immunotherapy. J Immunol 2001;167:5852-5861.
30. Romero P, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650.
31. Dunbar PR, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-6652.
32. Valmori D, et al. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol 2000;165:533-538.
33. Pittet MJ, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-715.
34. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996;19:266-277.
35. Anichini A, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651-667.
36. Pittet MJ, et al. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-7640.
37. Valmori D, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-1750.
38. Sensi M, et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 1995;92:5674-5678.
39. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995;16:176-181.
40. Dietrich PY, et al. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res 2001;61:2047-2054.
41. Blattman JN, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002;195:657-664.
42. Loftus DJ, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996;184:647-657.
43. Douek DC, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
44. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
45. Zippelius A, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002;195:485-494.
46. Rufer N, et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999;190:157-167.
47. Barton GM, Rudensky AY. Requirement for diverse, low-abundance peptides in positive selection of T cells. Science 1999;283:67-70.
48. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-1039.
49. Pinilla C, et al. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res 2001;61:5153-5160.
50. Ochsenbein AF, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-2238.
51. Berset M, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001;95:73-77.
52. Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 2001;94:551-557.
53. Yee C, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med 2000;192:1637-1644.
54. Aichele P,-Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med 1990;171:1815-1820.
55. Toes RE, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998;160:4449-4456.
56. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991;173:1007-1015.
57. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 micro-globulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-2051.
58. Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol 1999;162:3566-3573.
59. Jeannin P, et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 2000;1:502-509.
60. Miconnet I, et al. Cancer vaccine design: A novel bacterial adjuvant for peptide-specific CTL induction. J Immunol 2001;166:4612-4619.
61. Miconnet I, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002;168:1212-1218.
62. Bednarek MA, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 1991;147:4047-4053.
63. Speiser D, et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32:731-741.
64. Cormier JN, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
65. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
66. Pittet MJ, et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001;7:796s-803s.
67. Valmori D, et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002;168:4231-4240.
68. Romero P, et al. CD8+ T-cell response to NY-ESO-1: Relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res 2001;7:766s-772s.
69. Chen JL, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000;165:948-955.
70. Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J. Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 2000;85:829-838.
71. Tourdot S, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000;30:3411-3421.
72. Tangri S, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen dass I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001;194:833-846.
73. Valmori D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000;60:4499-4506.
74. Rimoldi D, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol 2000;165:7253-7261.
75. Ayyoub M, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunnol 2002;168:1717-1722.
76. Valmori D, et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 2001;61:509-512.
77. Romero P, et al. T Cells in Tumor Immunity. Mannheim, Germany: Wiley-VCH; 2002.
78. Haanen JB, et al. In situ detection of virus- and tumor-specific T-cell immunity. Nat Med 2000;6:1056-1060.
79. Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT. Cutting edge. In situ tetramer staining of antigen-specific T cells in tissues. J Immunol 2000;165:613-617.
80. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964-5968.
81. Dickinson AM, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002;8:410-414.